AstraZeneca unbranded effort urges sufferers to "Rethink COPD"

Share this article:
AstraZeneca unbranded effort urges sufferers to "Rethink COPD"
AstraZeneca unbranded effort urges sufferers to "Rethink COPD"
AstraZeneca is rolling out an unbranded COPD education campaign featuring comedian and actor Robert Klein.

The campaign, dubbed RethinkCOPD, is aimed at getting sufferers to consider their options with respect to diet, exercise and, of course, medication.

“For a lot of these patients, it's really about getting through their day,” said senior brand communications manager Dana Settembrino. “It's a struggle to get out of bed in the morning, it's a struggle to brush their teeth, and they want to be independent. It's all about getting them to talk to their doctor and start to think differently about this condition. There's not a lot known about it, and there's a stigma associated with it because most people have gotten it from smoking.”

Klein, a 67-year-old Bronx-born performer whose career has spanned Broadway roles and HBO comedy specials, features on the campaign's website (www.RethinkCOPD.com), where he'll discuss his diagnosis and the steps he's taken to keep his COPD in check. The campaign also features 15-second broadcast PSAs aimed at driving traffic to the Website.

The tagline of the aspirational campaign is “People with COPD are expecting more.” AstraZeneca worked with agencies Edelman, Cadient and Digitas Health on it.

The company's Symbicort, indicated for COPD as well as asthma, is not mentioned in the effort.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...